SEC Form 4 · accession 0000899243-15-009132
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Louis
Officer — See Remarks
Period of report
Dec 1, 2015
Accepted (ET)
Dec 2, 2015 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $10.42 | Dec 1, 2015 | A | 85,000 | A | — | Dec 1, 2025 | Common Stock | 85,000 | 85,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F225% of the shares of common stock underlying this stock option award will vest on December 1, 2016. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through December 1, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
Remarks
Global Chief Compliance Officer